Allergan, which is now part of AbbVie, will present new glaucoma research at the American Society of Cataract and Refractive Surgery (ASCRS) Virtual Annual Meeting on May 16. Data will include four virtual paper presentations analyzing safety and efficacy across several subgroups from the phase 3 studies of Durysta (bimatoprost implant) 10 mcg for intracameral administration. Durysta was approved by the FDA earlier this year as the first intracameral, biodegradable sustained-release implant indicated to reduce IOP in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
“The new analyses from our phase 3 ARTEMIS program demonstrate our commitment to furthering research and uncovering insights that may help physicians optimize the benefits of Durysta for patients,” Michael Robinson, MD, Vice President, Global Therapeutic Area Head, Ophthalmology, AbbVie, said in the news release. “Our work doesn’t end when one of our therapies receives regulatory approval because further research can potentially help improve care for patients with open-angle glaucoma or ocular hypertension needing IOP lowering.”
Allergan will present four abstracts as virtual paper presentations (all noted in local Eastern Daylight Time):
ASCRS Paper Session, SPS-304 Glaucoma Medications (Saturday, May 16, 3:00 – 4:30 PM, VM – 1, Virtual Room 7):
- Efficacy of Bimatoprost SR in Patients Stratified By Baseline IOP (≤25 or >25 mmHg): Phase 3 Study Results at Primary Database Lock
- Author: Weinreb, RN et al.
- Time: 3:00 – 3:05 PM
- Efficacy of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Eyes With Prior SLT: Phase 3 Study Results at Primary Database Lock
- Author: Brubaker, JW et al.
- Time: 3:05 PM – 3:10 PM
- Results of Phase 3 Study of Bimatoprost SR at Primary Database Lock: IOP Lowering in Patients With Prior Topical Therapy and Responder Rates
- Author: Craven, ER et al.
- Time: 3:10 – 3:15 PM
- Efficacy and Safety of Bimatoprost SR (BimSR) in Phakic and Pseudophakic Eyes: Phase 3 Study Results at Primary Database Lock
- Author: Walters, TR et al.
- Time: 3:15 – 3:20 PM
Full text of these abstracts can be accessed in the ASCRS Virtual Meeting Real Time Program. Those who have registered to attend the ASCRS Virtual Annual Meeting can view the presentations on Saturday, May 16, starting at 3:00 PM (EDT).
Durysta is a prostaglandin analog indicated for the reduction of IOP in patients with OAG or OHT. Durysta is an ophthalmic drug delivery system for a single intracameral administration of a biodegradable implant containing 10 mcg bimatoprost. Durysta should not be re-administered to an eye that received a prior Durysta. The drug is preloaded into a single-use applicator to facilitate the administration of the biodegradable implant directly into the anterior chamber of the eye.